Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
Drugs modulating the cystic fibrosis transmembrane conductance regulator (CFTR) protein, namely ivacaftor, lumacaftor, tezacaftor, and elexacaftor, are currently revolutionizing the management of patients with cystic fibrosis (CF), particularly those with at least one <i>F508del</i> vari...
Saved in:
Main Authors: | Eva Choong (Author), Alain Sauty (Author), Angela Koutsokera (Author), Sylvain Blanchon (Author), Pascal André (Author), Laurent Decosterd (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
by: L. Gómez-Ganda, et al.
Published: (2024) -
Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together
by: Rachel Kinuani, et al.
Published: (2024) -
Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
by: Linus Piehler, et al.
Published: (2023) -
Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor
by: Payal Patel, et al.
Published: (2023) -
Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023)